| __timestamp | Corcept Therapeutics Incorporated | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 18372000 | 79838000 |
| Thursday, January 1, 2015 | 15419000 | 121816000 |
| Friday, January 1, 2016 | 23844000 | 117633000 |
| Sunday, January 1, 2017 | 40376000 | 117456000 |
| Monday, January 1, 2018 | 75247000 | 171984000 |
| Tuesday, January 1, 2019 | 89017000 | 257452000 |
| Wednesday, January 1, 2020 | 114764000 | 477643000 |
| Friday, January 1, 2021 | 113864000 | 540684000 |
| Saturday, January 1, 2022 | 130991000 | 651496000 |
| Sunday, January 1, 2023 | 184353000 | 666563000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Corcept Therapeutics Incorporated and PTC Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
Corcept Therapeutics has shown a consistent increase in R&D expenses, growing from approximately $18 million in 2014 to nearly $184 million in 2023. This represents a tenfold increase, highlighting their strategic focus on expanding their research capabilities.
PTC Therapeutics, on the other hand, has pursued a more aggressive R&D strategy. Their spending surged from around $80 million in 2014 to over $666 million in 2023, marking an impressive 730% increase. This substantial investment underscores their commitment to pioneering new therapies.
Both companies exemplify the dynamic nature of the biotech industry, where R&D spending is pivotal to future growth and innovation.
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs PTC Therapeutics, Inc.
Research and Development Investment: Biogen Inc. vs Corcept Therapeutics Incorporated
Research and Development Investment: United Therapeutics Corporation vs Corcept Therapeutics Incorporated
Research and Development Investment: Viatris Inc. vs Corcept Therapeutics Incorporated
Exelixis, Inc. or Corcept Therapeutics Incorporated: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
R&D Insights: How Pharming Group N.V. and Corcept Therapeutics Incorporated Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Grifols, S.A. and Corcept Therapeutics Incorporated
R&D Insights: How Corcept Therapeutics Incorporated and ImmunityBio, Inc. Allocate Funds
R&D Insights: How Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc. Allocate Funds
R&D Insights: How PTC Therapeutics, Inc. and Xencor, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.